EISAI INC Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?
EISAI INC has thirteen approved drugs.
There are fifteen US patents protecting EISAI INC drugs.
There are four hundred and ninety-nine patent family members on EISAI INC drugs in forty-eight countries and sixty-one supplementary protection certificates in eighteen countries.
Summary for EISAI INC
| International Patents: | 499 |
| US Patents: | 15 |
| Tradenames: | 9 |
| Ingredients: | 8 |
| NDAs: | 13 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for EISAI INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | RX | Yes | Yes | RE46965*PED | See Plans and Pricing | Y | See Plans and Pricing | |||
| Eisai Inc | DAYVIGO | lemborexant | TABLET;ORAL | 212028-001 | Apr 7, 2020 | RX | Yes | No | 10,188,652 | See Plans and Pricing | Y | See Plans and Pricing | |||
| Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | AB | RX | Yes | Yes | 6,740,669*PED | See Plans and Pricing | Y | See Plans and Pricing | ||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | ||||
| Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EISAI INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-003 | Nov 14, 2008 | 8,076,362*PED | See Plans and Pricing |
| Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 022568-001 | Jul 23, 2010 | 4,895,841 | See Plans and Pricing |
| Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-002 | Oct 18, 2004 | 4,895,841 | See Plans and Pricing |
| Eisai Inc | LUSEDRA | fospropofol disodium | SOLUTION;INTRAVENOUS | 022244-001 | Dec 12, 2008 | 6,204,257 | See Plans and Pricing |
| Eisai Inc | HALAVEN | eribulin mesylate | SOLUTION;INTRAVENOUS | 201532-001 | Nov 15, 2010 | 6,469,182 | See Plans and Pricing |
| Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | 7,727,552 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
| ➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
| ➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
| ➤ Subscribe | Tablets | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | ➤ Subscribe | 2016-10-24 |
International Patents for EISAI INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 195282 | See Plans and Pricing |
| Mexico | 2007007836 | See Plans and Pricing |
| Japan | 2008525313 | See Plans and Pricing |
| Norway | 20031731 | See Plans and Pricing |
| Poland | 347211 | See Plans and Pricing |
| China | 101899026 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for EISAI INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1415987 | 15C0070 | France | See Plans and Pricing | PRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601 |
| 1087960 | 132011901976051 | Italy | See Plans and Pricing | PRODUCT NAME: ERIBULINA(HALAVEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/678/001-002, 20110317 |
| 0994864 | SPC/GB07/041 | United Kingdom | See Plans and Pricing | PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015 |
| 1300396 | 300565 | Netherlands | See Plans and Pricing | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723 |
| 1300396 | 132012902109980 | Italy | See Plans and Pricing | PRODUCT NAME: PERAMPANEL(FYCOMPA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/776/001 A EU/1/12/776/016, 20120723 |
| 1300396 | CA 2012 00052 | Denmark | See Plans and Pricing | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
